Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is Thymalin | Thymic Peptide Complex for Immunoregulatory Research

Research Use Only Notice. This article is for laboratory research and educational use only.

It discusses in vitro studies and controlled laboratory animal models. It is not a dosing, reconstitution, administration, medical, or veterinary guide.

The materials described here are not intended for human or veterinary use.

Thymalin is a mixture of low-molecular-weight peptides originally prepared from calf thymus tissue. It is not one single peptide with one fixed sequence or molecular weight.A 1997 paper reported that the dipeptide L-Glu-L-Trp, usually shortened to Glu-Trp or EW, was isolated from Thymalin by reversed-phase HPLC.[1] A later UPLC-MS study from the same research field reported that Lys-Glu (KE) and Glu-Asp-Pro (EDP) were also detected as minor components of the Thymalin mixture.[2]
What Is Thymalin

Much of the published research specifically involving Thymalin and its proposed short-peptide components has been conducted by Khavinson and collaborating researchers. Independent replication by unrelated laboratories remains limited.

This does not mean the findings are incorrect, but it means readers should not interpret the current evidence as a broad scientific consensus.

Thymalin and EW should not be treated as the same material.

Thymalin is a heterogeneous peptide mixture, whereas EW is a chemically defined dipeptide with the sequence H-Glu-Trp-OH. EW was reported as a component isolated from Thymalin and can also be manufactured synthetically.

Results obtained with EW cannot automatically be applied to the full Thymalin mixture, and results obtained with Thymalin cannot automatically be assigned to EW.

Molecular identity

Property Thymalin peptide complex EW dipeptide
Type of material Mixture of peptides from thymus tissue Single chemically defined dipeptide
Sequence No single sequence applies to the full mixture H-Glu-Trp-OH, abbreviated EW
Molecular formula No single formula applies to the full mixture C16H19N3O5
Molecular weight No single molecular weight applies to the full mixture 333.34 g/mol
Registry number 79621-14-0 is listed for Thymalin in the NLM MeSH database. This registry number identifies the named peptide complex or preparation and does not imply one fixed sequence, molecular formula, or molecular weight. 38101-59-6
Main quality-control approach Batch fingerprint, source information, peptide profile, and batch-to-batch comparison Sequence, HPLC purity, mass spectrometry identity, and peptide-content information

The formula, molecular weight, sequence, and CAS number shown for EW are listed in the PubChem record for Thymogen (CID 100094). Oglufanide is an international nonproprietary name associated with this molecule, while Thymogen is also used as a common or product-related name.

Product formulations should not be assumed to be identical to a pure EW reference standard.[3]

What researchers have studied

Researchers have studied Thymalin and related short peptides in cell cultures, tissue cultures, and laboratory animal models. The results vary by material, concentration, cell type, and test method, so the findings should be read as model-specific observations rather than general proof of biological effects.

One in vitro study tested Thymalin, EW, KE, and other short peptides in the THP-1 monocytic cell line. The authors reported changes in several cell-signaling, cytokine, and cell-adhesion measurements under the conditions used in that experiment.[4]

These results apply to that cell model and do not establish safety, effectiveness, or effects outside the laboratory setting.

An earlier organ-culture study tested Thymalin, Thymogen, and Vilon in thymus and spleen explants from young rats (1-day-old and 21-day-old). The reported response depended on the peptide, concentration, tissue, and age of the donor animals.[5]

This variation is another reason not to combine results from different peptide products or different experimental models.

Proposed gene-regulation mechanism

Some papers from the Khavinson research group propose that very short peptides may affect gene expression and may interact with DNA or other cell components. A 2023 study combined computer docking with in vitro tests of EW, KE, and Thymalin in cultured peripheral blood mononuclear cells.

The in vitro portion used cells obtained from four donors and should therefore be regarded as a small exploratory study rather than an independently validated mechanism.[6]

The computer model predicted possible DNA sequences that might interact with EW or KE, but a docking result is only a prediction. It does not prove that the peptide binds directly to that DNA sequence inside a living cell.

The same study reported changes in selected cytokine measurements in its in vitro model, but those changes do not by themselves prove that DNA binding caused the result.

Direct peptide-DNA binding should therefore be described as a proposed mechanism that still needs independent testing.

How Thymalin differs from other thymic peptides

Thymalin is also different from Thymosin Alpha-1 and thymopoietin. Thymosin Alpha-1 is a defined peptide with 28 amino acids.[7]

Bovine thymopoietin II was described as a 49-amino-acid polypeptide.[8] These materials have different sequences and compositions, so evidence for one should not be used as evidence for another.

How to read a COA

A certificate of analysis should match the type of material being sold.

A COA for synthetic EW should not be written in the same way as a COA for a mixed Thymalin preparation.

  • For synthetic EW: the COA should list the sequence, theoretical molecular weight, observed mass or mass-to-charge value, HPLC method, chromatogram, reported purity, batch number, and storage conditions.
  • For a Thymalin mixture: the COA should identify the tissue source and preparation type and provide a validated batch fingerprint with defined comparison criteria, total peptide or relevant content information, source and preparation traceability, and batch-to-batch similarity data. Additional process-related and microbiological tests should be included where relevant to the preparation and intended research use.
  • For either material: water, residual solvents, counterions, and net peptide content should be reported when they affect the amount of actual peptide in the vial.

HPLC area percentage shows the relative area of detected chromatographic peaks under a specific method. It does not by itself confirm the peptide sequence, the exact amount of peptide in the vial, or the absence of impurities that co-elute with the main peak.

Guidance on peptide reference standards recommends using more than one test, such as HPLC, mass spectrometry, amino-acid analysis, water testing, and residual-solvent testing, depending on the material and its intended laboratory use. That guidance primarily addresses synthetic therapeutic peptides and may not directly define mandatory specifications for tissue-derived peptide mixtures.[9]

LC-high-resolution mass spectrometry can help identify closely related peptide impurities that may be difficult to separate or identify by HPLC-UV alone.[10] An authentic and traceable COA documents the reported test results for a batch against the listed specifications.

It does not independently guarantee sample identity, method suitability, safety, or biological effectiveness for human or veterinary use.

Laboratory storage and handling

Storage and solvent choice should follow the batch-specific COA or stability data. For long-term storage, lyophilized peptide standards are commonly stored at −20°C to −80°C, depending on sequence-specific and batch-specific stability data.

Moisture exposure and repeated freeze–thaw cycles should be minimized. Protection from light is particularly relevant for photochemically sensitive sequences, including peptides containing aromatic residues such as tryptophan.

The cited peptide-handling guidance primarily addresses MS quantitative peptide standards and does not replace batch-specific stability studies for Thymalin or EW.[11]

Peptide solubility depends on sequence, salt form, counterion, pH, concentration, and solvent. A solvent that works for EW may not work for the full Thymalin mixture.

Researchers should test a small laboratory aliquot first and confirm that the material is fully dissolved before using it in an assay.

These instructions are laboratory handling notes only and are not administration or dosing instructions.

References

  1. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology. 1997;19(9-10):501-505. https://doi.org/10.1016/S0192-0561(97)00058-1
  2. Khavinson VK, Zhurkovich IK, Ryzhak GA, Mironova ES, Kovrov NG. Identification of short peptides: optimization of target therapeutic properties of the thymus medicine. Molekulyarnaya Meditsina. 2021;19(3):32-37. https://doi.org/10.29296/24999490-2021-03-05
  3. National Center for Biotechnology Information. PubChem Compound Summary for CID 100094, Thymogen (H-Glu-Trp-OH, C16H19N3O5, 333.34 g/mol, CAS 38101-59-6). https://pubchem.ncbi.nlm.nih.gov/compound/38101-59-6
  4. Avolio F, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences. 2022;23(7):3607. https://pubmed.ncbi.nlm.nih.gov/35408963/
  5. Chalisova NI, Khavinson VKh, Penniiaĭnen VA, Grigor’ev EI. Effect of thymus polypeptide fractions on the development of rat thymus and spleen in organ culture. Tsitologiia. 1999;41(10):889-894. https://pubmed.ncbi.nlm.nih.gov/10591126/
  6. Linkova N, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences. 2023;24(17):13377. https://pubmed.ncbi.nlm.nih.gov/37686182/
  7. Goldstein AL, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences of the United States of America. 1977;74(2):725-729. https://pubmed.ncbi.nlm.nih.gov/265536/
  8. Schlesinger DH, Goldstein G. The amino acid sequence of thymopoietin II. Cell. 1975;5(4):361-365. https://pubmed.ncbi.nlm.nih.gov/1171728/
  9. McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharmaceutical Research. 2023;40(6):1317-1328. https://pmc.ncbi.nlm.nih.gov/articles/PMC10338602/
  10. Li M, et al. Identification and accurate quantification of structurally related peptide impurities in synthetic human C-peptide by liquid chromatography-high resolution mass spectrometry. Analytical and Bioanalytical Chemistry. 2018;410(20):5059-5070. https://pubmed.ncbi.nlm.nih.gov/29862433/
  11. Hoofnagle AN, et al. Recommendations for the generation, quantification, storage and handling of peptides used for mass spectrometry-based assays. Clinical Chemistry. 2016;62(1):48-69. https://pmc.ncbi.nlm.nih.gov/articles/PMC4830481/

Research Use Only Disclaimer

Research Use Only: The Thymalin product described on this page is supplied for laboratory research use only and is not intended for human or veterinary use.

This article is provided for informational context regarding published laboratory research and general analytical and handling considerations, and does not constitute medical, clinical, veterinary guidance or treatment advice.